Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
Konrad ZuzdaWiktoria GrycukJacek MałyszkoMalyszko JolantaPublished in: Expert opinion on therapeutic targets (2022)
The precise mechanisms for regulating lipid metabolism, particularly in kidney disease, are poorly understood. Guidelines for lipid-lowering therapy for CKD are controversial. Several hypolipemic therapies are available, but compared to others, statin therapy is the most common. No clinical trial has evaluated the efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in preventing cardiovascular events or improving kidney function among patients with CKD or kidney transplant recipients. Attractive alternatives, such as PCSK9-small interfering RNA (siRNA) molecules or evinacumab are available. Additionally, several promising agents, such as cyclodextrins and the FXR/TGR5 dual agonist, INT-767, can improve renal lipid metabolism disorders and delay CKD progression. Drugs targeting mitochondrial dysfunction could be an option for the treatment of dyslipidemia and lipotoxicity, particularly in renal diseases.
Keyphrases
- cardiovascular events
- low density lipoprotein
- chronic kidney disease
- coronary artery disease
- fatty acid
- clinical trial
- cardiovascular disease
- cancer therapy
- clinical practice
- phase ii
- randomized controlled trial
- drug delivery
- study protocol
- open label
- combination therapy
- bone marrow
- drug induced
- mass spectrometry
- phase iii
- cell therapy